Department of Urology

Medicine & Life Sciences

1. Renal Cell Carcinoma 100%
2. Prostatic Neoplasms 72%
3. Urinary Bladder Neoplasms 55%
4. Neoplasms 46%
5. Nephroureterectomy 43%
6. Carcinoma 41%
7. Castration 33%
8. Recurrence 30%
9. Prostate-Specific Antigen 26%
10. Kidney 23%
11. Survival 23%
12. Neoplasm Metastasis 23%
13. Prostatectomy 22%
14. Prostate 20%
15. Therapeutics 20%
16. Nephrectomy 18%
17. cabazitaxel 15%
18. Japan 15%
19. Axitinib 14%
20. Urinary Bladder 14%
21. Adrenalectomy 14%
22. Drug Therapy 13%
23. Androgens 12%
24. Sunitinib 12%
25. Cystectomy 12%
26. Docetaxel 11%
27. Cisplatin 11%
28. Nivolumab 10%
29. Tomography 10%
30. Survival Rate 9%
31. Brachytherapy 9%
32. Bacillus 9%
33. Safety 9%
34. Sorafenib 9%
35. Urinary Tract 9%
36. Progression-Free Survival 8%
37. Multivariate Analysis 8%
38. Biopsy 8%
39. dehydroxymethylepoxyquinomicin 8%
40. Biomarkers 8%
41. Neoplasm Grading 7%
42. pembrolizumab 7%
43. Hydronephrosis 7%
44. Angiomyolipoma 7%
45. Ureter 6%
46. Renal Dialysis 6%
47. Genes 6%
48. Platinum 6%
49. Lymph Nodes 6%
50. Radiotherapy 6%
51. Urologic Neoplasms 6%
52. Aldosterone 6%
53. Interleukin-2 6%
54. Ureteral Obstruction 5%
55. Kidney Neoplasms 5%
56. C-Reactive Protein 5%
57. Angiotensin Type 1 Receptor 5%
58. gemcitabine 5%
59. Molecular Targeted Therapy 5%
60. Apoptosis 5%
61. Serum 5%
62. Lymph Node Excision 5%
63. Magnetic Resonance Imaging 5%
64. Retrospective Studies 5%
65. Hematuria 5%
66. Urologists 5%
67. Operative Time 5%
68. Lung 5%
69. Incidence 5%
70. Pneumoperitoneum 5%
71. Ultrasonography 5%
72. Pheochromocytoma 5%
73. Prostatic Hyperplasia 5%